Corrigendum: N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: A North Central Cancer Treatment Group (NCCTG) Trial (Ann Oncol (2010) 21 (493–497) DOI: 10.1093/annonc/mdp328)

W. W. Tan; D. W. Hillman; M. Salim; D. W. Northfelt; D. M. Anderson; P. J. Stella; R. Niedringhaus; A. M. Bernath; S. S. Gamini; F. Palmieri; E. A. Perez

doi:10.1093/annonc/mdx811

Corrigendum: N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: A North Central Cancer Treatment Group (NCCTG) Trial (Ann Oncol (2010) 21 (493–497) DOI: 10.1093/annonc/mdp328)

W. W. Tan, D. W. Hillman, M. Salim, D. W. Northfelt, D. M. Anderson, P. J. Stella, R. Niedringhaus, A. M. Bernath, S. S. Gamini, F. Palmieri, E. A. Perez

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

The following funding statement was missing from the original manuscript: ‘Supported by NIH grant U10CA025224 to the North Central Cancer Treatment Program.’ This has now been amended in the online version.

Original language	English (US)
Pages (from-to)	493-497
Number of pages	5
Journal	Annals of Oncology
Volume	29
Issue number	10
DOIs	https://doi.org/10.1093/annonc/mdx811
State	Published - Oct 2018

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1093/annonc/mdx811

Fingerprint

Dive into the research topics of 'Corrigendum: N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: A North Central Cancer Treatment Group (NCCTG) Trial (Ann Oncol (2010) 21 (493–497) DOI: 10.1093/annonc/mdp328)'. Together they form a unique fingerprint.

Cite this

Tan, W. W., Hillman, D. W., Salim, M., Northfelt, D. W., Anderson, D. M., Stella, P. J., Niedringhaus, R., Bernath, A. M., Gamini, S. S., Palmieri, F., & Perez, E. A. (2018). Corrigendum: N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: A North Central Cancer Treatment Group (NCCTG) Trial (Ann Oncol (2010) 21 (493–497) DOI: 10.1093/annonc/mdp328). Annals of Oncology, 29(10), 493-497. https://doi.org/10.1093/annonc/mdx811

Corrigendum: N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: A North Central Cancer Treatment Group (NCCTG) Trial (Ann Oncol (2010) 21 (493–497) DOI: 10.1093/annonc/mdp328). / Tan, W. W.; Hillman, D. W.; Salim, M. et al.
In: Annals of Oncology, Vol. 29, No. 10, 10.2018, p. 493-497.

Research output: Contribution to journal › Comment/debate › peer-review

Tan, WW, Hillman, DW, Salim, M, Northfelt, DW, Anderson, DM, Stella, PJ, Niedringhaus, R, Bernath, AM, Gamini, SS, Palmieri, F & Perez, EA 2018, 'Corrigendum: N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: A North Central Cancer Treatment Group (NCCTG) Trial (Ann Oncol (2010) 21 (493–497) DOI: 10.1093/annonc/mdp328)', Annals of Oncology, vol. 29, no. 10, pp. 493-497. https://doi.org/10.1093/annonc/mdx811

Tan WW, Hillman DW, Salim M, Northfelt DW, Anderson DM, Stella PJ et al. Corrigendum: N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: A North Central Cancer Treatment Group (NCCTG) Trial (Ann Oncol (2010) 21 (493–497) DOI: 10.1093/annonc/mdp328). Annals of Oncology. 2018 Oct;29(10):493-497. doi: 10.1093/annonc/mdx811

@article{f2794297c5b94c138b6e2b1d7a118ec8,

title = "Corrigendum: N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: A North Central Cancer Treatment Group (NCCTG) Trial (Ann Oncol (2010) 21 (493–497) DOI: 10.1093/annonc/mdp328)",

abstract = "The following funding statement was missing from the original manuscript: {\textquoteleft}Supported by NIH grant U10CA025224 to the North Central Cancer Treatment Program.{\textquoteright} This has now been amended in the online version.",

author = "Tan, {W. W.} and Hillman, {D. W.} and M. Salim and Northfelt, {D. W.} and Anderson, {D. M.} and Stella, {P. J.} and R. Niedringhaus and Bernath, {A. M.} and Gamini, {S. S.} and F. Palmieri and Perez, {E. A.}",

year = "2018",

month = oct,

doi = "10.1093/annonc/mdx811",

language = "English (US)",

volume = "29",

pages = "493--497",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "10",

}

TY - JOUR

T1 - Corrigendum

T2 - N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: A North Central Cancer Treatment Group (NCCTG) Trial (Ann Oncol (2010) 21 (493–497) DOI: 10.1093/annonc/mdp328)

AU - Tan, W. W.

AU - Hillman, D. W.

AU - Salim, M.

AU - Northfelt, D. W.

AU - Anderson, D. M.

AU - Stella, P. J.

AU - Niedringhaus, R.

AU - Bernath, A. M.

AU - Gamini, S. S.

AU - Palmieri, F.

AU - Perez, E. A.

PY - 2018/10

Y1 - 2018/10

N2 - The following funding statement was missing from the original manuscript: ‘Supported by NIH grant U10CA025224 to the North Central Cancer Treatment Program.’ This has now been amended in the online version.

AB - The following funding statement was missing from the original manuscript: ‘Supported by NIH grant U10CA025224 to the North Central Cancer Treatment Program.’ This has now been amended in the online version.

UR - http://www.scopus.com/inward/record.url?scp=85099722067&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85099722067&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdx811

DO - 10.1093/annonc/mdx811

M3 - Comment/debate

C2 - 29390054

AN - SCOPUS:85099722067

SN - 0923-7534

VL - 29

SP - 493

EP - 497

JO - Annals of Oncology

JF - Annals of Oncology

IS - 10

ER -

Corrigendum: N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: A North Central Cancer Treatment Group (NCCTG) Trial (Ann Oncol (2010) 21 (493–497) DOI: 10.1093/annonc/mdp328)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this